Antitumor activity of rapamycin in patients with recurrent PTEN-deficient glioblastoma
2008

Antitumor Activity of Rapamycin in Glioblastoma Patients

Sample size: 15 publication Evidence: moderate

Author Information

Author(s): Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J

Primary Institution: University of California, Los Angeles

Hypothesis

What is the effect of rapamycin on patients with recurrent PTEN-deficient glioblastoma?

Conclusion

The study found that rapamycin showed antitumor activity in some patients with recurrent PTEN-deficient glioblastoma.

Supporting Evidence

  • 50% of patients showed suppression of mTOR correlated with inhibition of tumor cell proliferation.
  • Preclinical data did not predict the response rates observed in the trial.
  • Activation of feedback loops may explain the diminished response rate in some patients.

Takeaway

Doctors tested a medicine called rapamycin on patients with a type of brain cancer, and it helped some of them feel better.

Methodology

Patients with recurrent PTEN-deficient glioblastoma were treated with rapamycin for one week, underwent resection, and continued therapy until tumor recurrence.

Limitations

Only 50% of patients responded to treatment, indicating variability in effectiveness.

Participant Demographics

Patients had recurrent glioblastoma with known PTEN loss.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0050008

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication